Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada.
Histopathology. 2014 Jan;64(2):226-33. doi: 10.1111/his.12242. Epub 2013 Nov 6.
LMO2 is a transcription factor that plays a key role in haematopoiesis. Expression of LMO2 has been demonstrated in germinal centre B cells, various B cell lymphomas and T lymphoblastic lymphoma/leukaemia (T-ALL), but has not been studied extensively in acute myeloid leukaemia (AML).
We studied LMO2 expression by immunohistochemistry in biopsies from a cohort of AML patients (n = 196) and correlated it with established prognostic factors such as age, bone marrow morphology and cytogenetic findings.
Forty per cent (79 of 196) of the samples from AML patients showed moderate/strong expression of LMO2 protein. LMO2 expression showed a significant positive correlation with normal cytogenetics (65% versus 24%, P < 0.0001) and a moderately negative correlation with complex karyotype [rs (98) = -0.218, P < 0.002]. AML associated with core binding factor [(t(8;21)/inv(16)/t(16;16)] had low LMO2 expression compared to diploid karyotype (29% versus 65%; P = 0.013). Expression of LMO2 protein exhibited an insignificant association with age (P = 0.197). Lower expression of LMO2 protein was noted in AML associated with myelodysplasia-related changes, compared to AML subtypes based on FAB classification (M0-M7) (21% versus 44%, P = 0.0187).
LMO2 is expressed in a subset of AML patients and is associated with normal karyotype, which is different from T-ALL, where specific translocation (11p13) mediates protein expression.
LMO2 是一种转录因子，在造血过程中发挥关键作用。LMO2 的表达已在生发中心 B 细胞、各种 B 细胞淋巴瘤和 T 淋巴母细胞淋巴瘤/白血病（T-ALL）中得到证实，但在急性髓系白血病（AML）中尚未广泛研究。
我们通过免疫组织化学研究了来自 AML 患者队列的活检样本中的 LMO2 表达，并将其与年龄、骨髓形态和细胞遗传学发现等既定的预后因素相关联。
40%（196 例 AML 患者中的 79 例）的样本显示 LMO2 蛋白中度/强表达。LMO2 表达与正常核型呈显著正相关（65%比 24%，P<0.0001），与复杂核型呈中度负相关[rs（98）=-0.218，P<0.002]。与核心结合因子相关的 AML（t（8;21）/inv（16）/t（16;16））与二倍体核型相比，LMO2 表达较低（29%比 65%；P=0.013）。LMO2 蛋白的表达与年龄无显著相关性（P=0.197）。与 FAB 分类（M0-M7）为基础的 AML 亚型相比，与骨髓增生异常相关改变相关的 AML 中 LMO2 蛋白表达较低（21%比 44%，P=0.0187）。
LMO2 在一部分 AML 患者中表达，并与正常核型相关，这与 T-ALL 不同，后者特定的易位（11p13）介导蛋白表达。
